Nixon Peabody
Bank of America
You are here:  Home  >  Biotech  >  Current Article

MannKind beats earnings estimates

By   /   Thursday, May 7th, 2020  /   No Comments

    Print       Email
Net losses at Westlake Village biotech firm MannKind fell to $9.32 million, or 4 cents per share for the first quarter, beating expectations of analysts as its chief product, Afrezza, saw revenue jump 58 percent. Sales of the inhalable insulin product rose to $8 million during the quarter ended March 31, while revenue from collaborations…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

Leave a Reply

Your email address will not be published. Required fields are marked *

You might also like...

SB County clears path for wine tasting rooms to reopen

Read More →